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Background: Point-of-care blood gas test results may beneﬁt therapeutic decision making by their immediate
impact on patient care. We evaluated the (pre-)analytical performance of a novel cartridge-type blood gas
analyzer, the GEM Premier 5000 (Werfen), for the determination of pH, partial carbon dioxide pressure (pCO2),
partial oxygen pressure (pO2), sodium (Na+), potassium (K+), chloride (Cl−), ionized calcium (iCa2+), glucose,
lactate, and total hemoglobin (tHb).
Methods: Total imprecision was estimated according to the CLSI EP5-A2 protocol. The estimated total error was
calculated based on the mean of the range claimed by the manufacturer. Based on the CLSI EP9-A2 evaluation
protocol, a method comparison with the Siemens RapidPoint 500 and Abbott i-STAT CG8+ was performed.
Obtained data were compared against preset quality speciﬁcations. Interference of potential pre-analytical
confounders on co-oximetry and electrolyte concentrations were studied.
Results: The analytical performance was acceptable for all parameters tested. Method comparison demonstrated
good agreement to the RapidPoint 500 and i-STAT CG8+, except for some parameters (RapidPoint 500: pCO2,
K+, lactate and tHb; i-STAT CG8+: pO2, Na+, iCa2+ and tHb) for which signiﬁcant diﬀerences between ana-
lyzers were recorded. No interference of lipemia or methylene blue on CO-oximetry results was found. On the
contrary, signiﬁcant interference for benzalkonium and hemolysis on electrolyte measurements were found, for
which the user is notiﬁed by an interferent speciﬁc ﬂag.
Conclusion: Identiﬁcation of sample errors from pre-analytical sources, such as interferences and automatic
corrective actions, along with the analytical performance, ease of use and low maintenance time of the in-
strument, makes the evaluated instrument a suitable blood gas analyzer for both POCT and laboratory use.
1. Introduction
Point-of-care (POC) blood gas analyses could help in therapeutic
monitoring and decision making of severely ill patients [1,2]. This is
especially true when biochemical parameters are exceeding the clinical
reference range, for which acute and eﬀective treatment is essential.
The last years, blood gas analyzers have become more sophisticated and
are able to measure, along whole blood pH, partial carbon dioxide
pressure (pCO2) and partial O2 pressure (pO2), several electrolytes
[sodium (Na+), potassium (K+), chloride (Cl−), ionized calcium
(iCa2+)], co-oximetry parameters [total hemoglobin (tHb), oxyhe-
moglobin (O2Hb), carboxyhemoglobin (COHb), methemoglobin
(metHb), deoxyhemoglobin (HHb)], glucose and metabolites (lactate,
total bilirubin). The availability of rapid test results might promote
earlier diagnosis and treatment decision making. Therefore, POC ana-
lyzers are attractive therapeutic instruments in acute patient care [3].
An important challenge in POC is maintaining consistent quality
control across all testing sites with a wide range of operators. QC pro-
https://doi.org/10.1016/j.clinbiochem.2018.01.007
Received 13 August 2017; Received in revised form 19 December 2017; Accepted 11 January 2018
⁎ Corresponding author at: Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium, De Pintelaan 185, 9000 Ghent, Belgium
E-mail address: matthijs.oyaert@uzgent.be (M. Oyaert).
Abbreviations: CLIA, Clinical Laboratory Improvement Amendments; RCPA, Royal College of Pathologists of Australasia; eTE, estimated total error; ATE, allowable total error; CV,
coeﬃcient of variation; SD, standard deviation; SLS, sodium lauryl sulphate; pCO2, partial carbon dioxide pressure; pO2, partial oxygen pressure; Na+, sodium; K+, potassium; Cl−,
chloride; iCa2+, ionized calcium; tHb, total hemoglobin; ICU, Intensive Care Unit; POC, point-of-care; QC, Quality Control
Clinical Biochemistry 53 (2018) 116–126
Available online 12 January 2018
0009-9120/ © 2018 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
T
cesses not only require running appropriate controls at regular inter-
vals, but also require thorough assessment of the analyzed results,
taking corrective actions when necessary, and documenting the process
in a systematic way. Prior to reporting patient results, each test result
should also be veriﬁed to identify any obvious error or interference that
may have occurred. However, this is not evident in a POC-setting.
Measurement of blood gas parameters by means of POC methods is
vulnerable to a number of pre-analytical errors. While common pre-
analytical errors, such as missing or wrong patient ID labels and in-
correct sampling, can aﬀect blood gas tests in the same way as other
laboratory tests, blood gas testing is more error-prone as some analytes
are gaseous and more vulnerable to a set of errors and interferences
[4,5].
In the present study, we evaluated the performance of the novel
GEM® Premier™ 5000 for measurement in whole blood of pH, pCO2,
pO2, Na+, K+, Cl−, iCa2+, glucose, lactate and tHb, and compared the
obtained results with the results of two other blood gas analyzers
available in our lab. In addition to this analytical performance eva-
luation, we put special attention to interfering substances that poten-
tially could inﬂuence co-oximetry and electrolyte results.
2. Materials and methods
2.1. Patient samples
Whole blood samples were randomly selected from those routinely
collected from patients at the Intensive Care Unit (ICU) of the Ghent
University Hospital and were prospectively included in the study.
Leftover samples were used in anonymous way, thereby waiving in-
formed consent according to the local ethical guidelines. The patient
samples were anaerobically drawn from arterial or venous lines fol-
lowing the CLSI C46-A2 guidelines [6] and collected into Siemens Ra-
pidlyte syringes, i.e. 3 mL syringe anti-coagulated with 70 IU lyophi-
lized electrolyte-balanced heparin (Siemens Healthcare, Sudbury, UK).
The samples were manually transported to the POC blood gas analyzers.
The analysis of the samples occurred on site, randomized on the dif-
ferent analyzers.
2.2. Werfen GEM Premier 5000
The GEM Premier 5000 (Werfen, Barcelona, Spain) is a novel cri-
tical care analyzer providing rapid analysis of whole blood samples in a
POC or central laboratory setting. This cartridge-type blood gas ana-
lyzer comprises all components necessary for analysis in a single closed
PAK, including electrochemical sensors, reagents, an optical cell for CO-
oximetry measurements, sampling stylus and waste container. This in-
strument is claiming an intelligent quality management technology that
replaces periodic analysis of external liquid controls with software,
internal process control solutions and calibration validation solutions
that continually assess the functionality of the instrument. In addition,
the analyzer has been designed to automatically initiate and document
corrective actions after malfunction in an analytical channel of analy-
tical interference.
We evaluated the analytical performance of the Werfen GEM
Table 1
Evaluation of total imprecision (CV%) on the GEM Premier 5000. Deviations from the preset criteria (Ricos and/or Lab) are indicated in bold.
Analyte Total imprecision Criteria
Level Mean SD CV (%) Ricos (%) Lab (%) i-STAT CG8+ (%) Manufacturer (%)
pH Low 7.133 0.007 0.10 0.1 0.2 0.1 0.3
Medium 7.372 0.007 0.09 0.1 0.2 0.1 0.3
High 7.581 0.003 0.04 0.1 0.2 0.1 0.3
pCO2, mmHg Low 14.0 0.000 0.0 2.4 7.6 3.3 17.9
Medium 37.7 0.931 2.5 2.4 2.7 1.4 7.1
High 90.0 2.041 2.3 2.4 7.6 1.5 4.0
pO2, mmHg Low 31.8 1.771 5.7 4.8 5.1 3.0 16.1
Medium 87.0 2.643 3.0 4.8 1.7 2.5 5.7
High 349.5 13.952 4.0 4.8 5.1 2.3 5.0
Na+, mmol/L Low 124.1 0.521 0.4 0.9 0.9 0.4 1.6
Medium 139.6 0.824 0.6 0.9 1.0 1.2 1.4
High 154.0 0.495 0.3 0.9 0.9 0.5 1.3
K+, mmol/L Low 2.4 0.000 0.0 6.8 1.9 0.0 10.4
Medium 4.6 0.026 0.6 6.8 1.9 1.4 5.3
High 7.7 0.062 0.8 6.8 1.9 0.6 3.5
Cl−, mmol/L Low 85.6 0.558 0.7 0.6 1.7 – 2.5
Medium 108.5 0.575 0.5 0.6 1.7 – 2.5
High 141.8 0.575 0.4 0.6 1.7 – 2.5
iCa2+, mmol/L Low 0.64 0.005 0.8 0.9 2.1 0.9 7.8
Medium 1.16 0.009 0.8 0.9 1.4 0.9 5.0
High 1.59 0.018 1.1 0.9 2.1 0.9 5.0
Glucose, mg/dL Low 43.1 1.465 3.4 2.3 12.0 0.4 6.5
Medium 102.0 2.117 2.1 2.3 6.0 1.1 5.0
High 383.5 5.617 1.5 2.3 12.0 2.5 5.0
Lactate, mg/dL Low 7.1 0.309 4.3 13.6 3.3 – 25.0
Medium 22.6 0.827 3.7 13.6 13.6 – 8.0
High 66.5 0.685 1.0 13.6 11.1 – 7.5
tHb, g/dL Low 7.7 0.133 1.7 1.4 1.4 1.7 4.5
Medium 14.7 0.132 0.9 1.4 1.4 2.0 2.4
High 21.0 0.165 0.8 1.4 1.4 1.0 2.4
Abbreviations: CV%: coeﬃcient of variation; n, number of measurements; Lab (%): long-term laboratory RP500 imprecision results.
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Premier 5000 (Werfen, Barcelona, Spain) in comparison with the
Siemens RapidPoint 500 analyzer (RP500, Siemens Healthcare,
Sudbury, UK) and the Abbott i-STAT handheld analyzer using the
CG8+ cartridge (Abbott Point of Care, East Windsor, NJ). All analyzers
were handled according to the manufacturer's instructions. Speciﬁc
attention was given to the performance characteristics of the iQM2
system for the detection of interferences on blood gas results.
2.3. Evaluation protocol
2.3.1. Imprecision, analytical deviation and estimated total error
To determine the total imprecision of the GEM Premier 5000,
aqueous QC material (Werfen GEM System Evaluator level 1, 2 and 3)
was used. Each analyte was tested at three concentration levels (low,
intermediate and high). A single lot of every level of control material
was used throughout the study (lot nrs. 1515, 2516, 3518). QC mate-
rials were aspired manually into the instruments.
The total imprecision was determined according to the CLSI EP5-A3
evaluation protocol [7]. For each level, two aliquots of test material
were analyzed within a single run per day, during 20 consecutive days.
The standard deviation (SD) and coeﬃcient of variation (CV) of the
observed data were calculated following the CLSI EP5-A2 guideline.
According to this protocol, precision is estimated separately for each
level and analyte tested. The obtained precision estimates were com-
pared to the Ricos desirable speciﬁcations [8], intra-laboratory long-
term Siemens RapidPoint 500 auto-QC and Abbott CG8+ QC im-
precision data (own, unpublished data) and the speciﬁcations provided
by the manufacturer [9].
We investigated whether the result of the ﬁrst measurement on the
ﬁrst 5 days was within the target interval as claimed by the manu-
facturer in the GEM System evaluator leaﬂet.
The analytical deviation, which could serve as a surrogate marker
for bias, was constructed by calculating the diﬀerence between the
mean result and the middle value of the target interval claimed by the
manufacturer. The estimated total error was calculated from the total
imprecision and the analytical deviation by use of the formula: esti-
mated total error = │analytical deviation│+ 1.65 × total impreci-
sion. A comparison against the desirable speciﬁcations was made
[8,10–11].
2.3.2. Method comparison
The results obtained with the GEM Premier 5000 were compared to
the Abbott i-STAT handheld analyzer using the CG8+ cartridge
(Abbott Point of Care, East Windsor, NJ) and the Siemens RapidPoint
500 analyzer (RP500, Siemens Healthcare, Sudbury, UK) according to
the CLSI EP9-A2 guidelines [12]. For glucose and tHb, method
Table 2
Analytical deviation and estimated total error results for the GEM Premier 5000 against the preset criteria. Deviations from the preset criteria (Ricos, Lab and/or manufacturer) are
indicated in bold.
Analyte Results Criteria
Level Measured mean Middle of target intervala Estimated TE (%) ATE Ricos ATE Lab Manufacturer
Target interval Within range? ATE
pH Low 7.14 7.13 0.3 – 0.6b 7.09–7.17 Yes 0.6
Medium 7.37 7.37 0.2 – 0.5b 7.33–7.41 Yes 0.5
High 7.58 7.57 0.2 – 0.5b 7.53–7.61 Yes 0.5
pCO2, mmHg Low 14.0 13 7.7 5.7 22.7c 10–16 Yes 35.7
Medium 37.0 36 6.9 5.7 8.0c 31–41 Yes 14.3
High 88.4 90 5.5 5.7 8.0c 81–99 Yes 5.7
pO2, mmHg Low 31.0 29 16.1 – 5.0b 19–39 Yes 29.0
Medium 87.4 90 7.9 – 5.0b 80–100 Yes 10.2
High 349.4 360 9.5 – 15.4b 328–392 Yes 2.4
Na+, mmol/L Low 124.2 124 0.9 4.6 1.2c 119–129 Yes 3.2
Medium 139.8 141 1.8 4.6 1.0c 136–146 Yes 2.8
High 154.2 156 1.7 4.6 0.9c 150–162 Yes 2.6
K+, mmol/L Low 2.4 2.4 0.0 16.0 – 2.1–2.7 Yes 20.8
Medium 4.6 4.6 0.9 16.0 – 4.2–5.0 Yes 10.6
High 7.6 7.6 1.9 16.0 – 7.1–8.1 Yes 6.5
Cl−, mmol/L Low 85.2 85 1.3 1.5 5.0c 80–90 Yes 4.7
Medium 108.2 108 1.1 1.5 5.0c 103–113 Yes 3.7
High 141.4 142 1.1 1.5 5.0c 137–147 Yes 2.8
iCa2+, mmol/L Low 0.64 0.64 1.7 2.0 1.0b 0.56–0.72 Yes 1.6
Medium 1.16 1.15 1.9 2.0 1.4b 1.06–1.24 Yes 0.9
High 1.58 1.56 3.0 2.0 2.1b 1.46–1.66 Yes 0.6
Glucose, mg/dL Low 44.6 49 14.6 5.5 10.0b 40–58 Yes 13.0
Medium 104.6 106 4.8 5.5 18.0b 94–118 Yes 5.8
High 377.2 382 3.7 5.5 36.0b 350–414 Yes 1.6
Lactate, mg/dL Low 7.0 7 7.2 30.4 10.0b 5–10 Yes 50.0
Medium 23.4 23 7.8 30.4 – 19–28 Yes 16.0
High 66.6 67 2.3 30.4 33.4b 59–74 Yes 5.5
tHb, g/dL Low 7.7 7.8 3.6 4.1 – 7.1–8.5 Yes 9.0
Medium 14.8 15.0 2.8 4.1 – 14.2–15.8 Yes 4.8
High 21.2 21.3 1.9 4.1 – 20.1–22.5 Yes 4.8
Abbreviations: CV%: coeﬃcient of variation; n, number of measurements; TE: Total Error; ATE: Allowable Total Error. The lab criteria on ATE are the criteria used for internal validation
of blood gas analysis results.
a Middle of the range provided by the manufacturer.
b RCPA criteria.
c CLIA criteria.
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comparisons with the Roche Cobas 8000 c701 hexokinase/glucose-6-
phosphate dehydrogenase method (Roche Diagnostics, Mannheim,
Germany) and Sysmex XN-1000 SLS-method (Sysmex cooperation,
Kobe, Japan) were performed, respectively. We aimed to include at
least 40 patient samples per analyte, with analyte concentrations dis-
tributed over the analytical measurement range to the extent possible.
The comparison was conducted over at least 5 operating days. Due to
pre-analytical considerations, specimen testing was performed in
singlet instead of duplicate. The order of analysis on the test and
comparative instrument was random. Instruments were installed side-
by-side so that the time interval between measurements was as short as
possible (max 1–2 min). All measurements were conducted by one
single operator and the samples were handled according to the avail-
able guidelines [6] to minimize bias due to pre-analytical errors. After
being introduced into the ﬁrst analyzer, possible air bubbles generated
by the aspiration process in the remainder of the blood sample were
removed immediately. Subsequently, the sample was reclosed with an
airtight cap and thoroughly remixed by hand prior to analysis on the
second analyzer.
2.3.3. Interference studies
Potential interferences were investigated on CO-oximetry and
electrolyte concentrations by spiking whole-blood samples with serial
dilutions of triglycerides, hemolysate, methylene blue and benzalk-
onium on the GEM Premier 5000 as well as on the RapidPoint 500.
Prior to spiking the sample with the possible interfering substance, a
blank heparin anticoagulated whole-blood sample of a healthy
volunteer was collected and mixed for 20 min. The oxygenated whole-
blood sample was divided into diﬀerent aliquots. Along with the
measurement of the sample with the possible interferent, a blank he-
parin anticoagulated whole-blood sample without interferent was
tested at the same time. For each aliquot, the spiked volume and ﬁnal
volume were kept constant (200 μL and 4 mL, respectively). Each
concentration of the possible interfering substance was evaluated on
both analyzers in triplicate. Signiﬁcant diﬀerences in samples with and
without the interferent were investigated by means of a Student t-test.
Each spiked sample was compared against the blank sample.
Interference of lipemia was evaluated using Intralipid® (Baxter,
Lessines, Belgium) to obtain 5 ﬁnal lipemic whole blood samples with
concentrations ranging from 0.2 to 2.0%. Interference of hemolysis was
studied by freezing 5 lithium-heparin samples of a volunteer during
diﬀerent times to obtain diﬀerent degrees of hemolysis. The degree of
hemolysis was measured on the Roche Cobas 8000 c702 (Roche
Diagnostics, Mannheim, Germany) using the Serum Index assay.
Interference of methylene blue (Merck, Darmstadt, Germany) was
assessed using a 1000 mg/L solution in saline to obtain 4 ﬁnal con-
centrations of methylene blue in whole blood samples of 10, 40, 80 and
100 mg/L. Potential interference of benzalkonium (Merck, Darmstadt,
Germany) was investigated by diluting a 1 mg/mL stock solution of
benzalkonium in saline to obtain 2 ﬁnal concentrations of 5 and 10 mg/
L.
2.4. Statistical analysis
Before statistical analysis, all data were subjected to an outlier de-
tection and rejection procedure according to the CLSI EP9-A2 protocol
[12]. Patient sample based method comparisons were evaluated by
calculating Spearman rank correlation coeﬃcients and the slope and
Fig. 1. Method comparison between GEM Premier 5000 between Roche Cobas 8000 and Roche Cobas 8000 for glucose (A) and between GEM Premier 5000 and Sysmex XN-1000 for tHb
(B). Passing and Bablok regression analysis showing the identity line and 95% conﬁdence interval for the regression line (1). Bland and Altman mean diﬀerence plots (2). The y-axis
represents the relative diﬀerence (%) between results obtained with both analyzers and the x-axis represents the average of the test analyzers. The solid lines represent the mean
diﬀerence and the limits of agreement (± 1.96 SD of the diﬀerences). The dashed lines represent the 95% conﬁdence intervals around the upper and lower limit of agreement.
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intercept using Passing and Bablok regression analysis. For each slope
and intercept, two-sided 95% conﬁdence intervals (CI) were calculated
[13]. Secondly, using Bland-Altman diﬀerence plots, relative mean
diﬀerences between the methods were visualized, along with limits of
agreement which were deﬁned as the mean diﬀerence ± 1.96 times
the standard deviation of the diﬀerences [14]. The allowable total error
was used to estimate whether the mean diﬀerence was clinically re-
levant. All statistical analyses were performed using Medcalc (Software
version 15.6.1; Mariakerke, Belgium).
3. Results
3.1. Total imprecision and estimated total error
We evaluated the analytical performance of pH, blood gases (pCO2,
pO2), electrolytes (iCa2+, Na+, K+ and Cl−), glucose, lactate, and tHb.
The total imprecision (CV%) determined for the GEM Premier 5000
against the preset quality speciﬁcations is presented in Table 1. Overall,
the results for total imprecision are acceptable, except for some para-
meters, for which the preset Ricos [pCO2 (medium), pO2 (low), Cl−
(low), Glucose (low), iCa2+ (high) and tHb (low)], internal lab [pO2
(low and medium), lactate (low) and tHb (low)] or i-STAT CG8+ [pCO2
(medium and high), pO2 (low, medium and high), K+ (high), iCa2+
(high) and glucose (low and medium)] criteria are not reached. The
total imprecision criteria as speciﬁed by the manufacturer were met.
The estimated total error results for the GEM Premier 5000 against
the preset quality speciﬁcation are presented in Table 2. For pCO2 (low
and medium), pO2 (low, medium and high), glucose (low and high),
Na+ (medium and high) and iCa2+ (low, medium and high), the preset
quality speciﬁcations are not met. For each parameter, the measured
mean fell within the target range as claimed by the manufacturer
(Table 2).
Bland and Altman mean diﬀerence between the Roche Cobas 8000
and the GEM Premier 5000 revealed a deviation of 1.9% for glucose
(Fig. 1A).
3.2. Method comparison
The results of the Spearman rank correlation, Passing and Bablok
regression analysis and Bland and Altman mean diﬀerences between
the GEM Premier 5000, RP500 and i-STAT CG8+ are summarized in
Table 3. Due to accidental analyzing errors (aspiration or calibration
errors), our method comparison studies have diﬀerent amounts of
samples for the evaluation of the various analytes. As there were only a
limited number of CG8+ cartridges available for analysis on the i-
STAT, the number of samples included in the method comparison be-
tween the GEM Premier 5000 and i-STAT CG8+ is lower.
Spearman rank correlation analyses yielded generally high corre-
lation coeﬃcients ranging from 0.889 to 0.992 for both analyzers being
correlated with the GEM Premier 5000 (Table 3). Especially for pCO2,
signiﬁcant systematic (intercept≠ 0) and proportional (slope≠ 1)
diﬀerences were observed between the GEM Premier 5000 and RP500
(Table 3). Also for K+ and lactate, systematic diﬀerences were noted.
Bland and Altman plots showed good agreement between the GEM
Premier 5000 and RP500 (Fig. 2). For all analytes, the mean relative
diﬀerences were within allowable error limits, with exception of pCO2
[−7.2% vs. 5.7% (Ricos)], pO2 [−7.4% vs. 5.0% (RCPA)], iCa2+
[−2.9% vs. 2.0% (Ricos)] and tHb [4.2% vs. 4.1% (Ricos)]. With the
exception of lactate, no apparent concentration dependency of the ob-
served mean diﬀerences was observed (Fig. 2 I2). For glucose (cf. supra)
and tHb, mean diﬀerences between the GEM Premier 5000 and hex-
okinase method on the Roche Cobas 8000 and sodium lauryl sulphate
(SLS) method on the Sysmex XN-1000 were determined, respectively.
These diﬀerences (glucose: 1.9%; tHb: −2.2%) were within the preset
Ricos total error criteria. Passing and Bablok regression analysis also
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revealed no signiﬁcant diﬀerences between the blood gas analyzer and
the respective analyzers (Fig. 1).
The slope of the regression equations for the i-STAT CG8+ was
never signiﬁcantly diﬀerent from 1 (Table 3). For one analyte (pO2), the
intercept was signiﬁcantly diﬀerent from 0. Bland and Altman plots
showed good agreement between the GEM Premier 5000 and i-STAT
(Fig. 3). For all analytes, the mean relative diﬀerences were within
allowable error limits, except for pO2 [−11.9% vs. 5.0% (RCPA)], Na+
[1.4% vs. 1.2% (CLIA)], iCa2+ [−4.4% vs. 2.0% (Ricos)] and tHb
[−10.7% vs. 4.1% (Ricos)]. No concentration dependency was found in
the diﬀerence plots (Fig. 3).
It should be noted that the layered data for some parameters in
Figs. 2 and 3 reﬂect roundings of results by the analyzer. However, the
IQM technology does not rely on these rounded values, but uses the
precise raw measurement data.
3.3. Interference studies
No signiﬁcant changes due to the presence of triglycerides (up to
1%) or methylene blue (up to 100 mg/L) were detected on co-oximetry
results on both the RP500 and GEM Premier 5000. However, the user of
the instrument is made aware of the possibility of a false result by
generation of parameter speciﬁc ﬂags (“high turbidity” or “absorbance
error”) in case of triglyceride concentrations of 1% or higher on the
outprint next to the co-oximetry results on the GEM Premier 5000
(Table 4). For methylene blue, no ﬂags were generated on both ana-
lyzers (Table 4).
On the contrary, signiﬁcantly higher Na+, K+ and iCa2+ con-
centrations were measured in samples spiked with benzalkonium
compared to blank samples. At a benzalkonium concentration of
10 mg/L, a speciﬁc ﬂag was generated on the GEM Premier 5000 (“On
the last sample, interference was detected on sodium, potassium and calcium
concentrations, probably due to benzalkonium”), but not on the RP500.
Signiﬁcantly higher potassium concentrations were also obtained in
samples with a high degree of hemolysis (hemolysis index> 88). In the
hemolysed samples, no speciﬁc ﬂags were generated on any instrument
(Table 4).
4. Discussion
Use of POCT requires easy-to-use devices with preferably little
maintenance tasks. Cartridge-type analyzers seem to fulﬁll these re-
quirements as they consolidate all these requirements in one or more
cartridges. In early studies evaluating the performance of blood gas
analyzers, non-standardized protocols were often used and performance
goals were lacking or arbitrarily chosen [15–22]. With the availability
of cartridge-type blood gas analyzers, evaluation studies using more
standardized protocols became available. Several studies have estab-
lished the analytical performance of earlier generations of GEM in-
struments [22–26]. In the present study, a performance evaluation of
the novel generation GEM Premier 5000 cartridge-type blood gas
analyzer was performed using widely applied CLSI-protocols.
The imprecision of the GEM Premier 5000 was acceptable, with
slightly higher variation coeﬃcients for some parameters than the
preset criteria (Table 1). These deviations from the preset criteria may
at least partly be explained by the manual introduction of control ma-
terial. Our results are in accordance with the imprecision results of two
other studies on earlier generation GEM instruments [23–24,26]. Al-
though these variations are higher than the preset criteria that are
partly based on our current long-term internal quality control results,
they are only of minor clinical importance.
We evaluated whether the measured mean fell within the target
interval as claimed by the manufacturer and assessed whether the es-
timated total error was within the preset speciﬁcations. Large but
clinically irrelevant deviations were observed both for pCO2 and pO2 on
the low (estimated total error 7.7% and 16.1%, respectively) and
medium (estimated total error 6.9% and 7.9%, respectively) levels
(Table 2).
In addition to blood gas analyses, the measurement of glucose and
lactate concentrations has gained importance on POC analyzers.
Especially for glucose, a large analytical deviation (−9.0%) and total
error (14.6%) were observed for the low control level, which might
aﬀect clinical decision making. Given the current emphasis on strict
blood glucose control at ICU, the performance of glucose determina-
tions is an important issue. Therefore, we performed an additional
method comparison with the hexokinase method on the Roche Cobas
8000 c701 used in our core laboratory, which showed acceptable re-
sults.
It should be noted that the real concentration of each analyte pre-
sent in the Werfen GEM System Evaluator control material is not ne-
cessarily the middle value of the speciﬁed concentration range.
According to the manufacturer, the measurement values should fall
within the preset concentration range and an exact value of bias cannot
be calculated by the user.
Other method comparison studies demonstrated diﬀerences be-
tween blood gas analyzers [23]. These diﬀerences become also ap-
parent in external quality control schemes. In our study, important and
often large diﬀerences between the GEM Premier 5000 and RP500
(pCO2 and pO2) and i-STAT CG8+ (pO2 and tHb), exceeding the preset
speciﬁcations, were found. These deviations may be attributed to the
diﬀerent sensor systems that react diﬀerently towards the same patient
matrix.
To ensure an accurate and prompt response to blood gas analyses,
control of pre-analytical variables is critical. It has been demonstrated
that the prevalence of unsuitable specimens referred for blood gas
analysis ranges between 1.2% and 3.7%, thereby representing a sub-
stantial hurdle to total quality management [27,28].
The iQM automated statistical QC assessment system on GEM in-
struments was introduced in 2003 by Westgard et al. [29]. iQM tech-
nology uses frequent measurements of internal process control solutions
to monitor measurement variation and signal abnormal drifts, and ap-
plies pattern recognition algorithms to identify the type of error and
consequently triggers appropriate corrective actions. The strength of
the technology lies in the continuous monitoring of potential points of
failure and automatic correction before a result is reported [30]. If an
interfering substance is detected during measurement of a sample, an
Intraspect® ﬂag is generated and process control solutions will be
analyzed after measurement to detect deviations from normality. If the
results of these control solutions fall outside the predeﬁned ranges, this
indicates the presence of micro-clots, micro-bubbles, CO-oximetry ab-
sorbance errors or an interfering substance (e.g. benzalkonium or
thiopental interference). This additional check takes approximately
75 s.
We demonstrated that the instrument is able to detect interference
Fig. 2. Method comparison between GEM Premier 5000 and RP500 for the diﬀerent analytes tested. Passing and Bablok regression analysis showing the identity line and 95% conﬁdence
interval for the regression line (1). Bland and Altman mean diﬀerence plots comparing analytes (2). The y-axis represents the relative diﬀerence (%) between results obtained with both
analyzers and the x-axis represents the average of the test analyzer and the RP500 values. The solid lines represent the mean diﬀerence and the limits of agreement (± 1.96 SD of the
diﬀerences). The dashed lines represent the 95% conﬁdence intervals around the upper and lower limit of agreement.
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from benzalkonium, a large lipophilic compound frequently used as
disinfectant in hospitals, on electrolyte measurements [31]. By gen-
eration of an appropriate ﬂag, the user is informed that a result (either
Na+ or iCa2+) is invalid, although subsequent samples would not be
aﬀected. This is of interest as clinicians and nurses are often not aware
of the inﬂuence of these substances on laboratory results. On the RP500
device, the user is not aware of this inﬂuence, since the interference is
not mentioned on the print-out but is only available in the event log of
the device. In addition, we investigated potential interference of li-
pemia and methylene blue, two compounds that strongly absorb in the
same spectrophotometric region as hemoglobin derivatives. No inter-
ference of methylene blue, used as an antidote in nitrite-induced me-
themoglobinemia [32], was found. This is satisfying, as methylene blue
is known to hinder the monitoring of methemoglobinemia treatment
which relies on repeated MetHb measurement [33]. Likewise, no
interference of lipemia was encountered, although a ﬂag informing the
user was generated.
In vitro hemolysis, i.e. breakdown of erythrocytes occurring during
collection, management, transportation or storage of biological sam-
ples, is a substantial problem in laboratory diagnostics and is likely to
introduce bias in blood gas analyses [34]. Manufacturers should de-
velop instrumentation capable of identifying interfering substances in
whole blood [35]. Interference of hemolysis on blood gas analysis was
evaluated and revealed spuriously elevated K+ concentrations. How-
ever, neither the GEM Premier 5000 nor other available blood gas
analyzers are currently capable of generate ﬂaggings informing users of
the spuriously elevated concentrations.
Along with the acceptable analytical performance characteristics,
technical features, fast measuring time and iQM2 technology (i.e. result
available 45 s after aspiration if no interference is detected), the GEM
Fig. 3. Method comparison between GEM Premier 5000 and i-STAT CG8+ for the diﬀerent analytes tested. Passing and Bablok regression analysis showing the identity line and 95%
conﬁdence interval for the regression line (1). Bland and Altman mean diﬀerence plots (2). The y-axis represents the relative diﬀerence (%) between results obtained with both analyzers
and the x-axis represents the average of the test analyzer and the i-STAT CG8+ values. The horizontal lines represent the mean diﬀerence and the limits of agreement (± 1.96 SD of the
diﬀerences).
Fig. 3. (continued)
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Premier 5000 was found an easy-to-use instrument (single disposable
cartridge concept, storage at room temperature, cartridge auto-valida-
tion and 31-day cartridge stability) requiring hardly no maintenance.
Future enhancements could consist of the integration of an automatic
blood-sample mixing system that, along with the iQM2 technology,
further diminishes the inﬂuence of the pre-analytical phase on blood
gas results.
In summary, the analytical performance of this novel cartridge-type
blood gas analyzer is in line with the results of other studies. The
strength of this analyzer lies in the pre-analytical detection capabilities
that function on every sample and provide an additional safeguard
against reporting erroneous results due to interferences. These results,
together with the favorable practicability of the instrument, demon-
strate that this cartridge-type blood gas analyzer is suitable for both
POC and laboratory use.
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Table 4
Interference results. Summary of interferences tested on CO-oximetry and electrolyte concentrations. For each interference, we indicate whether or not the instrument generates an
analyzer ﬂag and whether the results are reported.
Interferent Interference on Interference? Analyzer ﬂag? Results reported?a Ref
RP500 GEM 5000 RP500 GEM 5000 RP500 GEM 5000
Lipemia CO-oximetry of Hb-derivatives No No No Yes Yes Yes [36,38]
Methylene blue CO-oximetry of Hb-derivatives No No No No Yes Yes [33,37]
Benzalkonium Electrolytes (K+, Na+, iCa2+) Yes Yes No Yes No Yes [31]
Hemolysis Electrolytes (K+) Yes Yes No No Yes Yes [35]
a By analyzer
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